western yew (Taxus brevifolia). It is commonly used in the treatment of breast, ovary, lung, and other cancers; however, it causes significant side effects. Therefore, finding other anti-cancer treatments to combine with Taxol and which can decrease its toxicity is highly desirable. Red ginseng acidic polysaccharide (RGAP), isolated from Korean ginseng (Panax ginseng), was combined with Taxol and its effect on the activity and safety profile of Taxol assessed. Previous studies of Korean ginseng have shown its potential as an immunomodulator and anti-cancer agent.1 The current study evaluated the combination treatment against sarcoma and melanoma in mice. Efficacy of Taxol and RGAP were based on tumor weight and lifespan of the mice injected with sarcoma and melanoma. Treating the mice with singular Taxol (5 or 15 mg/kg) or just RGAP (25 mg/kg) preparations did not significantly increase the lifespan of mice compared with control mice. However treatment with RGAP (25 mg/kg) combined with Taxol (15 mg/kg) resulted in a 42.8 % increase in survival of test animals as compared to treatment with Taxol alone. The combination treatment resulted in complete tumor inhibition in 6 of 14 mice
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.